KSKeishi Sugimachi

Keishi Sugimachi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Keishi Sugimachi has a total of 307 co-authors. Here are the top co-authors by number of shared publications:

  • Masaru Morita

    Department of Gastroenterological Surgery, NHO Kyushu Cancer Center, Fukuoka, Japan

    13 shared publications
  • Tomohiro Iguchi

    Department of Hepatobiliary‐Pancreatic Surgery National Hospital Organization Kyushu Cancer Center Fukuoka Japan

    10 shared publications
  • Yohei Mano

    Department of Hepatobiliary and Pancreatic Surgery NHO Kyushu Cancer Center Fukuoka Japan

    9 shared publications
  • Tomonari Shimagaki

    Department of Hepatobiliary and Pancreatic Surgery NHO Kyushu Cancer Center Fukuoka Japan

    8 shared publications
  • Emi Onishi

    Department of Hepatobiliary and Pancreatic Surgery, NHO Kyushu Cancer Center, Fukuoka, Japan

    7 shared publications
  • Yasushi Toh

    Department of Gastroenterological Surgery NHO Kyushu Cancer Center Fukuoka Japan

    7 shared publications

Latest Publications

  • Tumor burden and liver function stratify outcomes after hepatic resection for BCLC stage B hepatocellular carcinoma: A multicenter retrospective cohort study

    by Norifumi Iseda, Shinji Itoh, Takeo Toshima, Takashi Motomura, Hiroto Kayashima, Mizuki Ninomiya, Yo-Ichi Yamashita, Kengo Fukuzawa, Yukiko Kosai, Kazutoyo Morita, et al.

  • Symptom presentation at diagnosis as a biological risk indicator in both resectable and unresectable pancreatic ductal adenocarcinoma

    by Takahiro Tomino, Keishi Sugimachi, Lingaku Lee, Takeshi Kurihara, Emi Onishi, Yusuke Niina, Terumasa Hisano, Rie Sugimoto, Naomichi Koga, Yuta Kasagi, et al.

  • Open Access

    Survival Outcomes of Gemcitabine–Cisplatin–S‐1 Versus Gemcitabine–Cisplatin in Unresectable Biliary Tract Cancer: A Multicenter Retrospective Study With a Focus on Conversion Surgery

    by Hisashi Kosaka, Masahiko Kinoshita, Satoshi Yasuda, Satoru Kakizaki, Rie Sugimoto, Jun Sakata, Kiyonori Yamai, Takeshi Hatanaka, Yusuke Yamamoto, Toshifumi Sato, et al.

    Background: Gemcitabine plus cisplatin (GC) has been the global standard for advanced biliary tract cancer (BTC). The triplet regimen gemcitabine–cisplatin–S‐1 (GCS) demonstrated superiority in the MITSUBA trial, but its real‐world effectiveness remains unclear. We compared survival outcomes of GCS versus GC, focusing on conversion surgery (CS). Methods: We retrospectively analyzed 542 patients with unresectable BTC treated between 2017 and 2024 at 19 Japanese institutions. Patients received GC ( n = 310) or GCS ( n = 232). Survival was evaluated using multivariable Cox regression, 90‐day landmark analysis, and propensity score matching (PSM) to adjust for baseline imbalances. Results: Patients treated with GCS achieved greater tumor shrinkage (median −23.0% vs. –10.0%, p = 0.014) and a higher CS rate (16.4% vs. 4.5%, p < 0.001) than GC. Median progression‐free survival was 8.6 versus 5.4 months ( p = 0.002), and median overall survival (OS) was 17.2 versus 11.6 months ( p = 0.006). In multivariable analysis, GCS was associated with a lower risk of death (HR 0.80, 95% CI 0.65–0.98, p = 0.035), with consistent results after PSM. Fifty‐two patients underwent CS, with comparable perioperative safety and R0 resection rates between regimens. Patients who underwent CS achieved markedly longer OS; in the overall cohort, median OS was 31.0 months in the GCS with CS group and not reached in the GC with CS group ( p = 0.131). Conclusions: Treatment with GCS was associated with longer survival compared with GC in unresectable BTC, alongside a higher rate of conversion surgery, which was associated with favorable long‐term outcomes.

  • Open Access

    Gemcitabine + Cisplatin + S-1 Treatment for Advanced Cholangiocarcinoma: Cost-Effective, with Better Progression-Free Survival Versus Standard Treatment with Gemcitabine + Cisplatin + Durvalumab

    by Yusuke Morita, Rie Sugimoto, Miho Kurokawa, Yuki Tanaka, Takeshi Senju, Toshimitsu Ichimaru, Lingaku Lee, Yusuke Niina, Terumasa Hisano, Masayuki Furukawa, et al.

    Objectives: To evaluate the prognosis and costs of gemcitabine + cisplatin + S-1 (GCS) versus gemcitabine + cisplatin + durvalumab (GCD), the standard of care for advanced cholangiocarcinoma, in a prospective observational study. Methods: We enrolled 52 patients who received GCS as first-line treatment from April 2020 to April 2024 and 44 patients who received GCD from March 2023 to April 2024. Overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) were examined. Propensity score matching (PSM) was performed to balance baseline characteristics between the two groups, and OS, PFS and ORR were then analysed in the matched cohorts. Drug costs were compared until the end of treatment. Results: OS was not significantly different between GCS and GCD at 18.6 months (95% confidence interval [CI]: 13.3–21.9) (p = 0.0935) versus 12.2 months (95% CI: 7.5–16). PFS was 10.2 months (95% CI: 6.5–13.8) versus 6.2 months (95% CI: 3.2–8.8) for GCS versus GCD, respectively (p = 0.0151). The ORR was also higher for GCS (36.5%) than for GCD (15.9%) (p = 0.0234). Twenty-seven patients were included in the PSM analysis, which showed no significant differences in OS or ORR, and better PFS for GCS (9.3 months, 95% CI: 7.4–21.1 versus 4.8 months, 95% CI: 2.7–8.8; p = 0.007). The cost of GCS versus GCD was $6350 (95% CI: 2300–9800) versus $97,200 (95% CI: 69,400–138,800) by treatment end (p = 0.0001). Conclusions: GCS was significantly less expensive than GCD and showed comparable OS and better PFS.


  • Open Access

    Gemcitabine + Cisplatin + S-1 Treatment for Advanced Cholangiocarcinoma: Cost-Effective, with Better Progression-Free Survival and Objective Response Rates Versus Standard Treatment with Gemcitabine + Cisplatin + Durvalumab

    by Yusuke Morita, Rie Sugimoto, Miho Kurokawa, Yuki Tanaka, Takeshi Senju, Toshimitsu Ichimaru, Lingaku Lee, Yusuke Niina, Terumasa Hisano, Masayuki Furukawa, et al.

    Objectives: To evaluate the prognosis and costs of gemcitabine + cisplatin + S-1 (GCS) versus gemcitabine + cisplatin + durvalumab (GCD), the standard of care for advanced cholangiocarcinoma, in a prospective observational study. Methods: We enrolled 52 patients who received GCS as first-line treatment from April 2020 to April 2024 and 44 patients who received GCD from March 2023 to April 2024. Overall survival (OS), progression-free survival (PFS) and objective response rate (ORR) were examined. Propensity score matching (PSM) was performed to balance baseline characteristics between the two groups, and OS, PFS and ORR were then analysed in the matched cohorts. Drug costs were compared until the end of treatment. Results: OS was not significantly different between GCD and GCS at 12.2 months (95% confidence interval [CI]: 7.5–16) versus 18.6 months (95% CI: 13.3–21.9) (p=0.0935). P FS was 6.26 months (95% CI: 3.2–8.8) versus 10.2 months (95% CI: 6.5–13.8) for GCD versus GCS, respectively (p=0.0151). The ORR was also better for GCD (36.5%) than for GCS (15.9%) (p=0.0234). Twenty-seven cases were included in the PSM analysis, which showed n o significant differences in OS and b etter PFS (6.3, 95% CI: 2.8–9.3 versus 11.4, 95% CI: 6.2–15.0; p=0.0142) and ORR (14.8% versus 40.7%; p=0.0309) for GCS versus GCD, respectively. The cost of GCD versus GCS was 113,472 ± 72,198 versus 4622 ± 3109 US dollars by treatment end (p=0.0001). Conclusions: GCS was significantly less expensive than GCD and showed comparable OS and better PFS and ORR.

  • Open Access

    Combination of Ethoxybenzyl‐Diethylenetriamine Pentaacetic Acid‐Enhanced Magnetic Resonance Imaging and a Serum Biomarker Is Useful in the Diagnosis of Hepatic Sinusoidal Disorder After Chemotherapy Treatment

    by Tomonari Shimagaki, Keishi Sugimachi, Takahiro Tomino, Takeshi Kurihara, Emi Onishi, Yutaro Shimomura, Kenji Shinozaki, Masaru Morita

    Aim: Sinusoidal obstruction syndrome (SOS), also known as “blue liver (BL),” is a common hepatic injury following oxaliplatin‐based chemotherapy in patients with colorectal liver metastases (CRLM). Early non‐invasive identification of SOS is essential for safe hepatic resection and improved outcomes; however, this remains clinically challenging. Methods: We retrospectively analyzed 155 patients who underwent preoperative ethoxybenzyl‐diethylenetriamine pentaacetic acid‐enhanced magnetic resonance imaging (EOB‐MRI) and hepatic resection for CRLM between 2014 and 2022. Radiologists evaluated SOS on EOB‐MRI using a five‐point reticular signal grading scale. Aspartate aminotransferase to platelet ratio index (APRI) scores were calculated preoperatively. BL was confirmed intraoperatively based on characteristic liver discoloration. Correlations between EOB‐MRI scores, APRI, and clinical outcomes were analyzed using receiver operating characteristic curves, survival analysis, and multivariate statistics. Results: Of 70 patients treated with preoperative oxaliplatin, 25 (35.7%) exhibited intraoperative BL. Overall survival was significantly worse in the blue liver group ( p = 0.0338), although disease‐free survival did not differ significantly. Patients in the BL group had significantly higher APRI and EOB‐MRI scores ( p = 0.0028 and p < 0.0001, respectively). The combined EOB‐MRI assessment and APRI had the highest diagnostic ability for BL detection, yielding an area under the curve of 0.806, with 78.0% sensitivity and 67.7% specificity. Patients with high scores in both modalities exhibited significantly poorer overall survival. Conclusion: A combination of EOB‐MRI and APRI is a valuable non‐invasive tool for preoperative detection of SOS in patients with CRLM. This approach improves diagnostic accuracy, facilitates surgical planning, and may predict long‐term prognosis following hepatic resection.

  • Open Access

    Polarity Gene PARD6B Promotes Tumor Growth of Colorectal Cancer via Increasing MYC Expression

    by Kosuke Hirose, Takaaki Masuda, Hajime Otsu, Taro Tobo, Kiyotaka Hosoda, Tadashi Abe, Yusuke Nakano, Masahiro Hashimoto, Takanari Tatsumi, Tomohiko Ikehara, et al.

    Polarity genes form intracellular protein complexes that establish epithelial cell polarity and homeostasis for various normal cellular functions. Partitioning Defective 6B (PARD6B), a polarity gene, functions as a scaffold node for the Par protein complex. However, its contribution to colon cancer is not well understood. In this study, we showed that PARD6B regulates tumor progression in colorectal cancer (CRC). PARD6B is located on chromosome 20, which is frequently amplified in CRC, and its expression in CRC correlates with DNA copy number amplification, including enhancer regions. Immunohistochemistry and single‐cell analyses also showed that PARD6B expression was significantly higher in cancer cells. Furthermore, unlike other polarity gene groups comprising the Par complex, PARD6B mRNA expression was the only independent poor prognostic factor. In vitro and in vivo experiments revealed that PARD6B positively regulates cell proliferation and cell cycle progression. In silico analysis also showed that PARD6B expression positively regulated MYC expression, a pathway believed to be associated. Additional in silico and in vitro analyses supported the hypothesis that PARD6B regulates miR‐34c, which directly targets and represses MYC expression. Pan‐cancer analysis indicated that PARD6B is highly expressed in gastrointestinal tumors, including CRC, and that high PARD6B mRNA expression is a poor prognostic factor in other cancer types. In summary, highly expressed PARD6B can promote CRC growth by upregulating MYC expression while suppressing miR‐34c expression, making PARD6B a potential prognostic biomarker and therapeutic target for CRC.


  • Cachexia index as a prognostic marker in patients undergoing biliary tract cancer resection

    by Tomonari Shimagaki, Keishi Sugimachi, Takahiro Tomino, Emi Onishi, Naomichi Koga, Yuta Kasagi, Masahiko Sugiyama, Yasue Kimura, Masaru Morita

    Purpose This study investigated the relationship between the preoperative cachexia index (CXI) and long-term outcomes in patients who underwent radical resection for biliary tract cancer (BTC). Methods We analyzed 128 patients who underwent BTC resection at a single institute between 2014 and 2022. The diagnoses of the patients included intrahepatic cholangiocarcinoma (n = 27), perihilar cholangiocarcinoma (n = 17), distal cholangiocarcinoma (n = 36), gallbladder carcinoma (n = 20), and ampullary cholangiocarcinoma (n = 28). The relationship between CXI and long-term outcomes after BTC resection was investigated. CXI was calculated on the basis of the preoperative skeletal muscle index, serum albumin level, and neutrophil-to-lymphocyte ratio. Results The low-CXI group (36/69, 52.1%) had a significantly higher rate of lymph node metastasis than the high-CXI group (14/59, 23.7%). The multivariate analysis confirmed that lymph node metastasis, poor differentiation (poor), and inclusion in the low-CXI group were independently associated with disease-free survival (DFS) and overall survival (OS) in patients who underwent radical resection for BTC. After propensity score matching, the low-CXI group had a significantly worse prognosis than the high-CXI group in terms of both DFS and OS. Conclusion CXI may be a useful prognostic factor for DFS and OS after resection of BTC.


  • The EZ‐ALBI score as a prognostic tool for outcomes after resection of small hepatocellular carcinoma (≤3 cm)

    by Tomonari Shimagaki, Keishi Sugimachi, Takahiro Tomino, Emi Onishi, Takeo Toshima, Shinji Itoh, Takashi Maeda, Tomoharu Yoshizumi, Masaru Morita

    Purpose: Liver function is a key prognostic factor in patients with hepatocellular carcinoma (HCC). The albumin–bilirubin (ALBI) score is an objective method to assess liver function severity, but its calculation is complex and challenging to implement in clinical practice. This study evaluated the prognostic utility of the EZ‐ALBI score, which uses a simpler and more accessible calculation method, in patients undergoing resection for small HCC (≤3 cm).Methods: The study included 1161 patients who underwent hepatectomy for small HCC. Data from these patients were analyzed, with 837 patients in dataset A and 324 in dataset B, considering the differences in surgical procedures between facilities.Results: There was a strong correlation between the ALBI and EZ‐ALBI scores across all patients, with a correlation coefficient of 0.974 (p < 0.0001). Comparison between the EZ‐ALBI Grade 1 (n = 647) and Grade 2 (n = 514) groups showed that Grade 2 had significantly poorer liver function, shorter operative time, and higher rates of postoperative complications. In dataset A, patients in the EZ‐ALBI Grade 2 group had significantly worse overall survival than those in Grade 1 (p < 0.0001). Similar trends were observed in dataset B, where Grade 2 was associated with significantly worse disease‐free survival and overall survival. Univariate and multivariate analyses identified the EZ‐ALBI score as an independent prognostic factor for OS in both datasets, with Grade 1 patients showing a better prognosis.Conclusion: The EZ‐ALBI score is a valuable prognostic tool for assessing outcomes after resection of small HCC.


  • Pancreatic cancer secondary to biliary tract cancer associated with pancreaticobiliary maljunction: intraductal dissemination through the common channel

    by Keishi Sugimachi, Takahiro Tomino, Tomonari Shimagaki, Emi Onishi, Yutaka Koga, Kenichi Taguchi, Masayuki Furukawa, Terumasa Hisano, Rie Sugimoto, Masaru Morita

    Patients with pancreaticobiliary maljunction (PBM) have a high risk of biliary tract cancer (BTC). The risk of pancreatic cancer is also reported to be higher in patients with PBM compared to the general population; the underlying cause remains unclear. We report a 73-year-old man with widespread pancreatic cancer involving the entire pancreas. The patient previously underwent curative resection for gallbladder cancer and hilar cholangiocarcinoma concomitant with PBM. A total pancreatectomy was performed for the new pancreatic lesion. Histopathological examination revealed a papillary tumor predominantly composed of intraepithelial lesions that extended throughout the pancreatic duct, with skip lesions and irregular invasive foci at multiple sites within the duct. The morphological features and mucin profile were similar to those of the previous biliary lesions. Genetic analysis of the current lesion showed wild-type KRAS, GNAS, and PIK3CA genes consistent with the previous lesions, indicating that the pancreatic and biliary lesions were molecularly identical clones. Based on the clinicopathological findings and molecular analysis, we concluded that the BTC had spread intraluminally to the pancreatic duct through the common channel of the PBM, resulting in intraductal dissemination. Patients with PBM should be followed for pancreatic lesions, because of the risk of intraductal dissemination of BTC.